Conventional imaging and 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of patients with previously treated Hodgkin's disease.

@article{Filmont2004ConventionalIA,
  title={Conventional imaging and 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of patients with previously treated Hodgkin's disease.},
  author={J. -E. Filmont and Cecelia S Yap and Fred Chau-Yang Ko and Duska Vranjesevic and Andrew Quon and Daniel J. A. Margolis and Arash Safaei and Christos Emmanouilides and Daniel H. S. Silverman and Michael E. Phelps and Johannes G Czernin},
  journal={Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging},
  year={2004},
  volume={6 1},
  pages={47-54}
}
PURPOSE The aim of this study was to determine the ability of 2-deoxy-2-[(18)F]fluoro-d-glucose positron emission tomography (FDG-PET) to predict the clinical outcome of previously treated patients with Hodgkin's Disease (HD). PATIENTS AND METHODS Thirty-two patients were studied with PET within a median interval of 5.2 months after treatment. Conventional imaging (CI) performed within two months before PET included 2.9+/-1.2 imaging tests/patient. To determine the independent ability of FDG… CONTINUE READING